報價延遲最少15分鐘:2026/03/22 01:43 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.47 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.74/-0.12
|
|
企業價值
229.05M
|
| 資產負債 |
|
每股賬面淨值
1.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
77.36M
|
|
每股收益
1.57
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease. |
